Updated Jul 16, 2026 · Last SEC filing 2026-06-16
LENZ Therapeutics, Inc. (LENZ) has filed 7 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-16. 3 Form 8-K material event filings were reported by LENZ in the last 90 days. InsiderAlpha tracks every LENZ SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001815776 |
| Form 4 filings (90d) | 7 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Latest Form 4 filing | 2026-06-16 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| George Jeffrey P. | Director | P — Open-market purchase | 5.6K | $8.92 | $50K | SEC | |
| Schimmelpennink Evert B. | President, CEO and Secretary | P — Open-market purchase | 28.1K | $8.95 | $251K | SEC | |
| Chevallard Daniel R. | Chief Financial Officer | P — Open-market purchase | 7.5K | $8.57 | $64K | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 49.7K | $45.35 | $2.25M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 177 | $47.01 | $8K | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 123 | $47.01 | $6K | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 34.4K | $45.35 | $1.56M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 57.5K | $46.41 | $2.67M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 83.1K | $46.41 | $3.85M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 20.1K | $43.00 | $866K | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 40.9K | $43.00 | $1.76M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 24.4K | $41.59 | $1.01M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 49.5K | $41.59 | $2.06M | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 268 | $43.30 | $12K | SEC | |
| Versant Venture Capital VI, L.P. | Insider | S — Open-market sale | 132 | $43.30 | $6K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for LENZ Therapeutics, Inc. (LENZ). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1 | — |
| Drapkin Kimberlee C | 1 | — |
| Thunen Shelley B | 1 | — |
| MCCOLLUM JAMES W | 1 | — |
| Scheiner Zachary | 1 | — |
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in LENZ insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live LENZ dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.